Navigation Links
Physician Groups Urge Congress to Direct CMS to Adopt Unique Billing Codes for Biosimilars
Date:12/9/2015

WASHINGTON, Dec. 9, 2015 /PRNewswire-USNewswire/ -- On Wednesday, December 9, 2015, six groups representing a broad spectrum of physicians who prescribe biologics – Alliance for Patient Access, American Association of Clinical Endocrinologists, American College of Rheumatology, American Gastroenterological Association, Biologics Prescribers Collaborative, and Coalition of State Rheumatology Organizations – sent a letter to Senator Orrin Hatch (R-UT), urging Congress to direct Centers for Medicare & Medicaid Services (CMS) to adhere to current law that states that the calculation for reimbursing biosimilars shall be made separately, strongly implying that each biosimilar should have its own unique payment rate and HCPCS code.

In October, Senator Hatch, Chairman of the Senate Committee on Finance, voiced his opposition on the CMS proposal to place biosimilars of a single reference product into one Healthcare Common Procedure Coding System (HCPCS) code. Despite strong concerns from more than 75 patients, healthcare providers, stakeholder organizations, and twenty additional Senators, CMS finalized the Medicare reimbursement of biosimilars policy, placing all biosimilar products under the same billing and payment code. The Biologics Prescribers Collaborative along with the other five groups expressed their concern that "the coding policy will interfere with the ability to track and trace each biosimilar medicine, which could have grave patient safety implications."

As physicians who routinely prescribe biologic medicines and on behalf of professional organizations with numerous biologics prescribers as members, these physician groups believe that CMS must take an approach that is consistent with FDA's proposal for distinguishable names and adopt unique HCPCS J-codes for each biosimilar. The letter states, "a single HCPCS billing code and reimbursement rate for all biosimilars of a single reference product seriously jeopardizes these [patient-centered care] principles, undermining innovation, science and safety."

The groups call for CMS to set unique billing codes for biosimilars in support of patient-centered care and sound biologics prescribing.

The letter to Senator Hatch can be found below.

RELATED LINKS
http://biologicsprescribers.org/resources

December 9, 2015
The Honorable Orrin G. Hatch
Chairman
Committee on Finance
United States Senate
219 Dirksen Senate Office Building
Washington, D.C. 20510

Dear Senator Hatch:

On behalf of our members – physicians who routinely prescribe biologic medicines – we thank you for opposing the Centers for Medicare & Medicaid Services (CMS) proposal to place biosimilars of a single reference product into one Healthcare Common Procedure Coding System (HCPCS) code.

As you are aware, CMS has now finalized this policy in the 2016 Medicare Physician Fee Schedule without making changes. As a result, Medicare Part B reimbursement of biosimilars will be based on the weighted average of sales prices under each shared HCPCS code.

Under this policy, manufacturers of biosimilars will have no incentive to invest in making improved products with different attributes. The coding policy will also interfere with the ability to track and trace each biosimilar medicine, which could have grave patient safety implications.

We write to express our serious and continuing concerns with the CMS decision. As such, we urge you and other Members of Congress to direct CMS to adhere to current law that states that the calculation for reimbursing biosimilars shall be made separately, strongly implying that each biosimilar should have its own unique payment rate and HCPCS code.

As physicians who make complex medical decisions daily, we are committed to principles of patient-centered care and a clinically-sound prescribing process for biological products, including biosimilars. A single HCPCS billing code and reimbursement rate for all biosimilars of a single reference product seriously jeopardizes these principles, undermining innovation, science and safety.

Attached below this letter is the comment we submitted on September 1 to CMS explaining our reasoning and urging CMS to adopt unique HCPCS billing codes (J-codes) for each biosimilar, unless deemed by FDA to be "interchangeable" with the reference biologic.

Respectfully,

Alliance for Patient Access

American Association of Clinical Endocrinologists

American College of Rheumatology

American Gastroenterological Association

Biologics Prescribers Collaborative

Coalition of State Rheumatology Organizations

Comment on CMS-1631-P ("Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2016")

September 1, 2015
Andrew Slavitt, Acting Administrator
Centers for Medicare and Medicaid Services
Department of Health and Human Services
Hubert H. Humphrey Building, Room 445-G
200 Independence Avenue, SW
Washington, D.C. 20201

Dear Acting Administrator Slavitt:

As physicians who routinely prescribe biologic medicines and on behalf of professional organizations with numerous biologics prescribers as members, we write to urge adoption of unique Healthcare Common Procedure Coding System (HCPCS) billing codes (J-codes) for each biosimilar, unless a biosimilar is deemed by the FDA to be "interchangeable" with the reference biologic.

We do so based on principles arising from our commitment to patient centered care and a clinically sound prescribing process for biologics, including biosimilars. We believe the Centers for Medicare and Medicaid Services' (CMS) proposal to assign a single HCPCS billing code and reimbursement rate to all biosimilars of a single reference product seriously jeopardizes these principles, as follows:

Principle 1 - Science:  Biosimilars are not generic drugs. They can only be similar to their reference product, not identical like a small-molecule generic drug. Biosimilars, like all biologics, are large molecules grown in living systems. In treating biosimilars like generics, CMS ignores these fundamental facts, creating additional concerns outlined below.   

Principle 2 - Choice:  The CMS proposal would reduce the financial incentive for manufacturers to compete by bringing biosimilars to market. Access to a choice of biosimilars is important for our patients, especially where an individual patient's immune reaction may differ between drugs. 

By prioritizing price over all other product features, the CMS proposal would also deter innovation and may discourage manufacturers from investing in new indications. Despite important differences between products, hospitals and payers also could easily prefer the lowest cost biosimilar at any given time, reducing choice and potentially encouraging inappropriate non-medical switching back and forth between one biologic/biosimilar and another. One paradigm in treating patients with autoimmune disorders is to avoid changing therapies unnecessarily once an effective treatment has been established.

Principle 3 - Safety:  Like any biologic, a biosimilar can trigger immune and other reactions due to differences in patients' antibody profiles. In addition, each biologic medicine possesses unique properties and sensitivities in manufacturing and handling, making quick and accurate identification of accountable manufacturers imperative.  

To enable effective traceability, each biosimilar must be fully distinguishable in all its names and tracking codes, including HCPCS billing codes. The FDA's draft guidance on nonproprietary naming of biological products proposes distinguishable names, calling for biological products to bear a nonproprietary name that includes an FDA-designated suffix. The agency explained, "There is a need to clearly identify biological products to improve pharmacovigilance, and, for the purposes of safe use, to clearly differentiate among biological products that have not been determined to be interchangeable."

In addition, physicians and others in the U.S. primarily rely on a non-biologic's brand or nonproprietary generic name in reporting adverse events to the FDA.[i]  On the other hand, the FDA's Sentinel Initiative uses claims data, including HCPCS billing codes.[ii] [iii]     

Principle 4 - Consistency:  As physicians who contend with a highly complex healthcare system, we value consistency.  As noted above, the FDA is proposing distinguishable naming for all non-interchangeable biologics, an approach with which CMS should be consistent in establishing HCPCS billing codes.

The CMS proposal also makes no provision for the approval of interchangeable biosimilars.  In fact, by treating biosimilars like generics, the proposal seems to treat all biosimilars for a given reference product as interchangeable. Determinations of interchangeability must be made by FDA and based solely on scientific and medical considerations.  

Principle 5 - Research:  Many of the patients we treat contend with particularly challenging conditions, sending us to research literature to evaluate alternative treatment paths. Separate billing codes for biosimilars would facilitate claims-based research encompassing the differences between biologics, including biosimilars. By not differentiating between biosimilars, the CMS proposal would preclude important inquiries and significantly diminish the utility of the data that is collected. 

We believe a robust, competitive market based on differentiated benefits, including price, will deliver the promise of biosimilars to our patients. For that market to thrive, each biosimilar needs a separate HCPCS billing code, thereby recognizing biosimilars as a new category of medicine.

Thank you for this opportunity to share our views and commitment to patient centered care and sound biologics prescribing based on our principles of science, choice, safety, consistency and research.

Respectfully,

Alliance for Patient Access

American Association of Clinical Endocrinologists

American College of Rheumatology

Biologics Prescribers Collaborative

Coalition of State Rheumatology Organizations

North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

[i] Lietzan, E. F., et al., Biosimilar Naming:  How Do Adverse Event Reporting Data Support the Need for Distinct Nonproprietary Names for Biosimilars, The Food and Drug Law Institute, Vol. 3, Issue 6, March 27, 2013.  Accessed August 18, 2015. 

[ii] Gnadinger, Tracy, New Health Policy Brief:  The FDA's Sentinel Initiative, Health Affairs Blog, June 8, 2015, Accessed on August 18, 2015.

[iii] Mini-Sentinel, Distributed Database and Common Data Model, Accessed August 18, 2015.

 


'/>"/>
SOURCE Biologics Prescribers Collaborative
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. iRhythm Technologies Launches New iOS App Enabling Patients to Report Irregular Heartbeat Symptoms for Physician Diagnosis
2. Warner Chilcott to Pay $125 Million to Resolve Physician Kickback Allegations
3. Konica Minolta Medical Imaging Hosts Webinar on New Solutions to Improve Diagnostic Viewing, Workflow Optimization and Physician-Patient Collaboration
4. Pharmacos must adapt as physician communication preferences change rapidly, ZS report says
5. EHE International Certifies Personal Care Physicians, LLC as its newest partner
6. Bayer to Present Pulmonary Arterial Hypertension Data at American College of Chest Physicians (ACCP) Annual Meeting
7. Emerging Opportunities in the US Therapeutic Drug Monitoring (TDM) Market 2016: Hospitals, Commercial Labs, Physician Offices
8. Emerging Opportunities in the 2016 US Endocrine Function Testing Market: Hospitals, Commercial Labs, Physician Offices
9. Emerging Opportunities in the US Immunoprotein Diagnostic Testing Market 2016: Hospitals, Commercial Labs, Physician Offices
10. The Center for Personalized Education for Physicians Offers Prescribing Controlled Substances Course
11. Nations Top Cancer Physicians Gather in Chicago to Discuss New Era of Precision Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2019)... ... November 19, 2019 , ... Liquid nutrients have reigned supreme ... space have been transitioning to powdered nutrients because of the cost-effectiveness and ease of ... difficulty in combining essential macro and micronutrients, most nutrient companies package them separately, forcing ...
(Date:11/19/2019)... ... 18, 2019 , ... San Antonio-based businesses, Rodkeys and Massage ... sales through a new partnership announced today. This collaboration has the potential to ... A selection of Rodkeys branded non-THC CBD products are now available at more ...
(Date:11/19/2019)... ... 2019 , ... Respected Hollywood actor and film director, Laurence ... Laurence Fishburne. The program’s central focus is to inform the general public about ... be aired on the show, a new segment covering TMJD (Temporomandibular Disorder) and ...
Breaking Medicine Technology:
(Date:11/16/2019)... ... 15, 2019 , ... As demand for legal medical marijuana ... well-managed dispensaries becomes more and more important, both for consumers and as part ... online, custom cannabis business plans is now increasing its support for marijuana dispensary ...
(Date:11/15/2019)... MIAMI (PRWEB) , ... November 15, 2019 , ... ... Anxiety and Depression Association of America (ADAA) puts the current figures ... any form of treatment. Such mental health issues manifest in many different ways, ...
(Date:11/15/2019)... (PRWEB) , ... November 15, 2019 , ... ... and co-builds next-generation cybersecurity and data science companies with nation-state experienced technical teams ... of its second-annual DataTribe Challenge is Code Dx Inc ., based in ...
(Date:11/14/2019)... ... ... Inland Detox, Inc. is proud of and grateful for its Chef, Arturo Banuelos, ... Mexico. The Chefs Latinos Guanajuato Festival Gastronomico was held at La Hacienda San Cristobal ... November 9, 2019. The event featured a total of 18 renowned Chef’s from Latin ...
(Date:11/14/2019)... ... 14, 2019 , ... In a first of its kind ... have performed a pioneering coronary intervention with an Impella heart assist device ... The new procedure offers surgeons another option to help save the lives of ...
Breaking Medicine News(10 mins):